Celltrion, a major Korean biopharmaceutical firm, said Tuesday its fourth quarter net profit had skyrocketed from a year ...

Celltrion booth at inflammatory bowel disease research gathering Visitors attend a presentation by South Korean ...

Avtozma, which is Celltrion’s twelfth biosimilar to be approved by the EC, is a recombinant humanised monoclonal antibody ...

South Korean firm Celltrion announced that the European Commission (EC) has granted marketing authorization for Avtozma ...

Celltrion today announced that the European Commission (EC) has granted marketing authorization for Avtozma® (CT-P47), a ...

Celltrion's autoimmune disease treatment, Remsima, has surpassed 1.2 trillion won ($837 million) in annual sales, making it ...

Celltrion, a major Korean biopharmaceutical firm, said Wednesday it will buy back 100 billion won ($69 million) worth of its ...

Celltrion has secured marketing authorisation from the European Commission (EC) for Avtozma (CT-P47), a biosimilar to Chugai Pharmaceutical’s RoActemra (tocilizumab). The approval allows Avtozma ...

Celltrion announces 100 billion won share buyback, starts market purchase tomorrow Celltrion to start market share buyback ...

Celltrion announced on the 24th that it has received product approval from the European Commission (EC) for ACTEMRA ...

South Korea-based Celltrion today announced that the European Commission (EC) has granted marketing authorization for three ...

Celltrion today announced that the European Commission (EC) has granted marketing authorization for three products across two biosimilars: Eydenzelt® ...